GPN Vaccines is a private biotechnology company developing a vaccine against Streptococcus pneumoniae (the pneumococcus) – the world’s foremost bacterial pathogen. S. pneumoniae is responsible for causing life-threatening pneumonia, bacteraemia and meningitis, as well as otitis media (middle ear infections). Each year it causes 1-2 million deaths worldwide, killing more children than AIDS, malaria and tuberculosis combined. There are now 98 different serotypes of Streptococcus pneumoniae and the best vaccine currently on the market only protects against 13 of them. Gamma-PNTM – GPN Vaccines’ new S. pneumoniae vaccine is being developed to protect children and adults against all S. pneumoniae strains, regardless of strain serotype.
The mission of GPN Vaccines is to create an effective vaccine that protects against all Streptococcus pneumoniae strains, regardless of strain serotype.
GPN Vaccines’ vision is for a world in which all pneumococcal disease is preventable by a simple, cost effective vaccine.
GPN Vaccines’ Directors and Research team participated in the International Symposium on Pneumococci and Pneumococcal Diseases in Melbourne, Australia.
April 16, 2018
MEET US AT
World Vaccine Congress (US) | 14 – 17 April 2019 | Washington DC, USA
GPN Vaccines’ technology is a proprietary engineered strain of S. pneumoniae that lacks capsular polysaccharide, is avirulent and is safe to handle; and when cultured and inactivated with high-energy photons (“gamma-rays”), a whole cell gamma-irradiated pneumococcal vaccine is produced, which we call “Gamma-PNTM”.